HOUSTON, Nov. 2 /PRNewswire-FirstCall/ -- Tanox, Inc. today reported financial results for the third quarter ended Sept. 30, 2006.
Total revenue for the third quarter of 2006 was $15.3 million, compared to revenues of $8.3 million for the third quarter of 2005, and $12.7 million for the second quarter of 2006. Net royalty revenue from sales of Xolair(R) (omalizumab) was $10.2 million for the third quarter of 2006, compared to net Xolair royalty revenue of $7.7 million for the third quarter of 2005, and $9.9 million for the second quarter of 2006.
In addition to royalty revenue, Tanox recorded third quarter 2006 manufacturing-rights revenue of $2.6 million versus manufacturing-rights revenue of $650,000 for the third quarter of 2005, and $651,000 for the second quarter of 2006. Manufacturing-rights revenue is based on the quantity of Xolair produced, as defined in the company's collaboration agreement with Genentech, Inc. and Novartis Pharma AG.
Tanox also recorded net profit-sharing revenue of $2.4 million for the third quarter of 2006, compared to net profit-sharing revenue of $562,000(1) for the third quarter of 2005, and $1.2 million for the second quarter of 2006. Third quarter 2006 profit-sharing revenue represented the company's share of Novartis' net profits from U.S. sales of Xolair in the second quarter of 2006.
Manufacturing-rights revenue and profit sharing are recorded one quarter in arrears.
Tanox reported net income of $376,000, or $0.01 per share, for the third quarter of 2006, compared to a net loss of $3.4 million, or $0.08 per share, for the third quarter of 2005, and a net loss of $2.3 million, or $0.05 per share, for the second quarter of 2006.
(1)Recorded as deferred profit-sharing revenue, resulting from Novartis'
net profits from U.S. sales of Xolair in the first half of 2005.
Results for the third quarter of 2006 reflected the company's Jan. 1, 2006 adoption of Statement of Financial Accounting Standards No. 123R (FAS 123R). The impact of expensing employee stock compensation is reflected below:
Basic and Diluted Reported
Earnings Per Share Basic and
Before Stock Stock Diluted
Compensation Compensation Earnings
Expense Expense Per Share
Third Quarter 2006 $0.03 $(0.02) $0.01
Research and development costs for the third quarter of 2006 were $14.5 million, compared to $11.4 million for the third quarter of 2005, and $14.0 million for the second quarter of 2006. The year-over-year increase in research and development costs was attributed to the write off of prepaid expenses of $1.4 million associated with a manufacturing services agreement, increased manufacturing activities in preparation for planned clinical trials, increased spending for preclinical programs and employee stock compensation expense.
General and administrative expenses were $2.6 million for the third quarter of 2006, compared to $1.5 million for the third quarter of 2005, and $3.0 million for the second quarter of 2006. The majority of the year-over- year increase in general and administrative costs for the third quarter of 2006 was due to employee stock compensation expense and expenses related to business-development activities.
As of Sept. 30, 2006, Tanox had $177.5 million in cash and investments, compared to $164.5 million at Dec. 31, 2005. The increase in cash was due to a one-time net milestone payment of $12.8 million received in the first quarter of 2006, and increases in royalty, profit-sharing and manufacturing- rights revenues.
Recent and Third Quarter Company Highlights
* Tanox has received positive feedback from the FDA regarding its
proposed pivotal Phase 2b protocol for the next dose-finding clinical
trial of its lead clinical antibody, TNX-355. The Agency has
concurred that the trial, if appropriately designed, could be
considered pivotal as part of a registration program for TNX-355 in
HIV treatment-experienced patients. The company is in the latter
stages of discussions with the FDA and will provide an update on the
timing of future clinical trials once the discussions are complete.
* Tanox made an oral presentation at the 2006 Interscience Conference on
Antimicrobial Agents and Chemotherapy in September that provided
insight into the resistance profile of TNX-355. Results of in vitro
studies indicated that reduced susceptibility to TNX-355 does not
appear to alter the CD4 cell requirement for HIV entry.
* The company presented new Phase 2 clinical results at the 2006
International AIDS Conference in August that confirmed TNX-355, when
used in combination with an optimized background regimen of
antiretroviral drugs, produced a sustained virologic response in
treatment-experienced HIV patients through 48 weeks. As previously
reported, the study met its primary endpoint of mean viral-load
reduction from baseline at Week 24.
* Patient enrollment continued ahead of schedule, with three of six
cohorts completed, in a Phase 1 clinical trial of anti-IL-13 antibody
TNX-650 for the treatment of Hodgkin's lymphoma.
* The company initiated a second Phase 1 trial of TNX-650. The trial is
designed to evaluate the antibody as a potential treatment for
moderate-to-severe asthma. The trial is a randomized, double-blind,
placebo-controlled, dose-escalation study of the safety, tolerability
and pharmacokinetics of single doses of TNX-650 in healthy volunteers.
A total of 32 subjects are expected to be enrolled in four cohorts in
the study, which is being conducted at a single site in the U.S. TNX-
650 has the potential to be a therapeutic option for non-allergic
asthma patients, as well as asthmatics whose disease is not currently
"We delivered strong revenue growth in the third quarter due to the substantial impact of our Xolair alliance," said Danong Chen, Ph.D., president and chief executive officer. "As sales continued to increase, we experienced year-over-year growth in royalty revenue and considerable increases in manufacturing-rights revenue and profit sharing.
"In addition, we advanced our drug-development programs and took an important step forward with the expansion of our TNX-650 antibody program into clinical testing as a potential treatment for asthma."
The company anticipates breakeven cash burn in 2006. The revised forecast reflects lower than anticipated capital expenditures and the company's expectation that certain costs associated with continued development of TNX- 355 will now occur in 2007 and beyond.
Tanox will host a conference call for investors today at 10 a.m., EST. The conference call can be accessed at 1-800-591-6923 (domestic) or 1-617-614-4907 (international). The pass code is 4544-2572. Live audio of the call will be webcast on the Internet. The webcast can be accessed from the Tanox Web site at http://www.tanox.com in the Investor Relations section. An audio replay of the webcast will be available beginning at noon, EST, Nov. 2, 2006 through 11 a.m., EST, Dec. 2, 2006. Access phone numbers for the replay are 1-888-286-8010 (domestic) and 1-617-801-6888 (international); conference pass code 5361-7610.
About Tanox, Inc.
Tanox is a biotechnology company specializing in the development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is a viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiviral activity in Phase 2 clinical testing. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and is approved for marketing in the United States, Canada and major European countries. Tanox is based in Houston and has a manufacturing facility in San Diego. Additional corporate information is available at http://www.tanox.com .
This news release contains forward-looking statements regarding Tanox's expectations for net cash usage and the timing of clinical developments, as well as statements regarding the therapeutic potential for TNX-355 and TNX- 650. These statements are based on Tanox's current beliefs and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially due to a number of factors, including the continued market acceptance of Xolair(R); the results of our collaborators, Genentech and Novartis, in growing sales of Xolair; our ability to successfully recruit participants for clinical trials; the potential failure to achieve positive results in clinical trials; and the strength of our patent portfolio. The therapeutic potential of TNX-355 as a treatment for HIV-1-infected patients or TNX-650 as a treatment for Hodgkin's lymphoma and/or asthma is subject to the risks inherent in drug development. The conduct or timing of any future trials of TNX-355 can depend on many factors, including our discussions with the FDA, whether we choose to partner the program, and availability of sufficient quantities of clinical-trial material. Success in early stage clinical trials does not ensure that later-stage or larger-scale clinical trials will be successful, and the results achieved in later-stage trials may not be sufficient to meet applicable regulatory standards. Problems or delays may arise during clinical trials or in the course of developing, testing or manufacturing drugs. For more detailed information on the risks and uncertainties associated with Tanox's drug development and other activities, see Tanox's periodic reports filed with the Securities and Exchange Commission. The Tanox logo is a registered trademark with the U.S. Patent and Trademark Office.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands, except per-share data)
Summary of Operations
Three Months Ended Nine Months Ended
September 30, September 30,
2006 2005 2006 2005
Revenues, net $15,293 $8,347 $37,853 $21,652
development 14,491 11,402 42,432 35,156
development --- --- --- 13,680
administrative 2,611 1,515 8,368 5,270
expenses 17,102 12,917 50,800 54,106
Loss from operations (1,809) (4,570) (12,947) (32,454)
Other income, net 2,185 1,187 5,869 3,192
Net income (loss) $376 $(3,383) $(7,078) $(29,262)
Income (loss) per share
- basic and diluted $0.01 $(0.08) $(0.16) $(0.66)
Shares used in computing
income (loss) per share
Basic 44,836 44,063 44,861 44,596
Diluted 44,924 44,063 45,064 44,596
Employee stock compensation
expense included in
development $411 $--- $1,170 $---
administrative 387 --- 1,713 ---
Total $798 $--- $2,883 $---
Summary Balance Sheet Information
September 30, December 31,
Cash, cash equivalents and investments $177,468 $164,501
Property and equipment, net 29,868 31,214
Other assets 15,677 34,221
Total assets $223,013 $229,936
Liabilities and Stockholders' Equity:
Accounts payable, accrued
liabilities and deferred revenue $11,332 $16,495
Stockholders' equity 211,681 213,441
Total liabilities and stockholders' equity $223,013 $229,936
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGO
PRN Photo Desk firstname.lastname@example.orgTanox, Inc.